Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of 68Ga-FAPI PET/CT and 18FDG PET/CT Modalities in Gastrointestinal System Malignancies with Peritoneal Involvement.
Elboga U, Sahin E, Kus T, Cayirli YB, Aktas G, Okuyan M, Cinkir HY, Teker F, Sever ON, Aytekin A, Yılmaz L, Aytekin A, Cimen U, Mumcu V, Kilbas B, Eryilmaz K, Cakici D, Celen YZ. Elboga U, et al. Among authors: sever on. Mol Imaging Biol. 2022 Oct;24(5):789-797. doi: 10.1007/s11307-022-01729-x. Epub 2022 Apr 11. Mol Imaging Biol. 2022. PMID: 35411447
External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.
Yekedüz E, Karakaya S, Ertürk İ, Tural D, Uçar G, Şentürk Öztaş N, Arıkan R, Hızal M, Küçükarda A, Sever ÖN, Arslan Ç, Can O, Kılıçkap S, Yazgan C, Karadurmuş N, Şendur MA, Çiçin İ, Demirci U, Özgüroğlu M, Öksüzoğlu B, Ürün Y. Yekedüz E, et al. Among authors: sever on. Clin Genitourin Cancer. 2023 Feb;21(1):175-182. doi: 10.1016/j.clgc.2022.07.006. Epub 2022 Jul 16. Clin Genitourin Cancer. 2023. PMID: 35970759
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
Yekedüz E, Ertürk İ, Tural D, Karadurmuş N, Karakaya S, Hızal M, Arıkan R, Arslan Ç, Taban H, Küçükarda A, Öztaş NŞ, Sever ÖN, Uçar G, Can O, Şendur MA, Demirci U, Kılıçkap S, Çiçin İ, Öksüzoğlu B, Özgüroğlu M, Ürün Y. Yekedüz E, et al. Among authors: sever on. Future Oncol. 2021 Dec;17(35):4861-4869. doi: 10.2217/fon-2021-0717. Epub 2021 Nov 2. Future Oncol. 2021. PMID: 34726480
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study.
Yekedüz E, Tural D, Ertürk İ, Karakaya S, Erol C, Ercelep Ö, Arslan Ç, Sever ÖN, Kılıçkap S, Şentürk Öztaş N, Küçükarda A, Can O, Öksüzoğlu B, Şendur MA, Karadurmuş N, Ürün Y. Yekedüz E, et al. Among authors: sever on. J Cancer Res Clin Oncol. 2022 Dec;148(12):3537-3546. doi: 10.1007/s00432-022-04055-5. Epub 2022 May 26. J Cancer Res Clin Oncol. 2022. PMID: 35616728
The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors.
Yücel KB, Yekedüz E, Karakaya S, Tural D, Ertürk İ, Erol C, Ercelep Ö, Öztaş NŞ, Arslan Ç, Uçar G, Küçükarda A, Sever ÖN, Kılıçkap S, Can O, Yazgan SC, Öksüzoğlu B, Karadurmuş N, Şendur MA, Ürün Y. Yücel KB, et al. Among authors: sever on. Sci Rep. 2022 Oct 3;12(1):16559. doi: 10.1038/s41598-022-20056-3. Sci Rep. 2022. PMID: 36192500 Free PMC article.
24 results